TrialJournal of acquired immune deficiency syndromes (1999)2019

Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.

Margaret Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.